H.C. Wainwright initiated coverage of NeuroPace (NPCE) with a Buy rating and $18 price target NeuroPace is a commercial-stage medical device company focused on the development and marketing of a brain-responsive neuromodulation system that can deliver personalized, real-time treatment at the seizure source for patients with drug-resistant focal epilepsy, the analyst tells investors in a research note. The firm says the cutback after the one-year data readout from the NAUTILUS study presents an attractive entry point, as the data have no impact on the sales momentum in patients with focal epilepsy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NeuroPace: Buy Rating Affirmed Amid Promising NAUTILUS Study Outcomes and Favorable FDA Engagement
- Optimistic Outlook for NeuroPace: Buy Rating Justified by Subgroup Success and Growth Potential
- NeuroPace’s Promising Prospects: Buy Rating Affirmed Despite Initial Study Setback
- Leerink says NeuroPace results disappointing, sees hope on totality of data
- NeuroPace Announces Promising NAUTILUS Study Results